Apotea AB (publ) (APOTEA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Apotea AB (publ) stock SEK 39.50, price SEK 104, that is 62.1% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
23‑month range kr 55.15 – kr 120.20 · fair‑value band kr 21.18 – kr 56.01 · the kr 104.30 price screens above the kr 39.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Apotea AB (publ) in your weekly email
Every Wednesday you see whether Apotea AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Apotea AB (publ) operates an online pharmacy in Sweden.
Show moreShow less
The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements.
It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears.
In addition, the company offers services comprising leasing, leasing of personnel to related companies. and market contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Stock analysis
Apotea AB (publ) (APOTEA) currently trades at kr 104.30, while our model-based Fair Value estimate is kr 39.50, 62% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of kr 45.25 per share, and 0 of the 26 models we run sit above the kr 104.30 price.
Bear case: the Asset-Based group reads lowest at kr 5.40, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 21.18 (bear) to kr 56.01 (bull), the price of kr 104.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Apotea AB (publ) reported revenue of 7.2B SEK in FY2025 versus 4.6B SEK in FY2021, a compound +12.1%/yr. Reported net income was 229M SEK in FY2025, compounding +21.6%/yr from FY2021.
Key figures
Market cap 10.9B SEK (≈ $1.1B) Small · P/E ratio 45.2 · P/S ratio 1.43 · EPS (TTM) kr 2.31 · Dividend yield 0.6% · Net margin 3.2% · Return on equity 27.8% · Return on assets (EBIT) 59.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 89% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 40% fair-value upside, at −62%, APOTEA screens richer than that median.
Fair Value models
Bearkr 21.18Fair Value kr 39.50Bullkr 56.01
Price kr 104.30 · Downside -62.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 1.46 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+44.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+43.4%
Dividend (yield on the price)0.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 4%
2025 sits 163% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+43.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +40.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−62.1% · Bottom 25%
Profitability
Return on equity (12 months)27.8% · Top 25%
Return on assets11.6% · Top 25%
Net margin (12 months)3.2% · Above median
Operating margin (12 months)5.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.9% · Top 25%
Dividend yield (12 months)0.6% · Bottom 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Apotea AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/APOTEA
Frequently asked questions
Is Apotea AB (publ) (APOTEA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of kr 39.50 versus a price of kr 104.30, about 62% lower (overvalued).
What is the fair value of APOTEA?
Our model-based fair value for Apotea AB (publ) is kr 39.50 (as of Nov 6, 2026), built from audited fundamentals. The current price: kr 104.30.
What is the quality score of APOTEA?
Apotea AB (publ) has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Apotea AB (publ) (APOTEA)?
Our model-based price target is the fair value of kr 39.50 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario kr 21.18, optimistic scenario kr 56.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Apotea AB (publ) stock forecast for 2026?
Our models put fair value at kr 39.50, about 62% lower versus a price of kr 104.30 (overvalued). Cautious scenario kr 21.18, optimistic scenario kr 56.01. The calculation is refreshed regularly with new filings.
What is the revenue of Apotea AB (publ) (APOTEA)?
Apotea AB (publ) reported trailing-twelve-month revenue of about 7.6B SEK (latest available figure, as of Nov 6, 2026).
Does Apotea AB (publ) pay a dividend?
Apotea AB (publ) currently shows a dividend yield of 0.58% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Apotea AB (publ) (APOTEA) and when is the ex-dividend date?
Apotea AB (publ) pays a dividend of kr 0.6 per share a year, a dividend yield of 0.6%. The last ex-dividend date was May 27, 2026. The payout ratio is 26.0% of earnings. Free cash flow covers the dividend 1.88 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Apotea AB (publ) (APOTEA)?
For today's price to be fair in a discounted-cash-flow model, Apotea AB (publ) would have to grow free cash flow by +43.6 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +12.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of APOTEA use?
Our models discount Apotea AB (publ) at 11.0 %: a base by market capitalisation (small), country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Apotea AB (publ) that is +43.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Apotea AB (publ) (APOTEA) delivered so far?
Over the past 4 years revenue at Apotea AB (publ) grew +12.1 % a year. The price currently implies free-cash-flow growth of +43.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Apotea AB (publ) (APOTEA) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Apotea AB (publ) (+43.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Apotea AB (publ) (APOTEA)?
The free-cash-flow yield on the price is 1.08 %: that much free cash flow Apotea AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Apotea AB (publ) (APOTEA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Apotea AB (publ) it is kr 39.50 per share (as of Nov 6, 2026), against a price of kr 104.30. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Apotea AB (publ) stock overvalued or undervalued in 2026?
As of Nov 6, 2026, APOTEA trades above its calculated fair value: price kr 104.30, fair value kr 39.50, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of APOTEA?
No. The price is what the market pays today (kr 104.30); the fair value is what the company's own numbers justify (kr 39.50). For Apotea AB (publ) the two are kr 64.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Apotea AB (publ) worth?
The market values Apotea AB (publ) at about 10.9B SEK (market capitalisation, as of Nov 6, 2026). Per share that is kr 104.30; our models calculate a fair value of kr 39.50 per share.
What do the bullish and bearish scenarios say about APOTEA?
Our models span a range for Apotea AB (publ): cautious scenario kr 21.18, base kr 39.50, optimistic kr 56.01 per share (as of Nov 6, 2026, price kr 104.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of APOTEA?
Apotea AB (publ) trades at a price-to-earnings ratio of 45.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 39.50 is built from several models across several years. Other multiples: P/B 12.9, P/S 1.4, EV/EBITDA 24.0.
How solid is the balance sheet of Apotea AB (publ) (APOTEA)?
Balance-sheet figures for Apotea AB (publ) (as of Nov 6, 2026): return on equity 27.8%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is APOTEA from its 52-week high?
Apotea AB (publ) trades at kr 104.30, at its 52-week high of kr 104.30 and 89% above the low of kr 55.15 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 39.50 is for.
Which stocks are comparable to Apotea AB (publ)?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Apotea AB (publ) stock attractive at the current price?
The data as of Nov 6, 2026: price kr 104.30, calculated fair value kr 39.50 (−62%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of APOTEA calculated?
We run Apotea AB (publ) through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 39.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Apotea AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Apotea AB (publ) (APOTEA)?
The closing price on Nov 6, 2026 was kr 104.30. Our model-based fair value is kr 39.50, about 62% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Apotea AB (publ) right now?
The price sits above even our optimistic bull case (kr 56.01). The favourable scenario is already priced in. The model range is unusually wide (kr 21.18 to kr 56.01). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Apotea AB (publ)
How large is the market capitalisation of Apotea AB (publ) (APOTEA)?
The market capitalisation of Apotea AB (publ) is 10.9B SEK (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Apotea AB (publ) (APOTEA)?
The price-to-sales ratio of Apotea AB (publ) is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Apotea AB (publ) (APOTEA)?
Earnings per share at Apotea AB (publ) are kr 2.31 (price ÷ EPS = P/E 45.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Apotea AB (publ) (APOTEA)?
The dividend yield of Apotea AB (publ) is 0.6% (payout 26.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Apotea AB (publ) (APOTEA)?
The net margin of Apotea AB (publ) is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Apotea AB (publ) (APOTEA)?
The return on equity (ROE) of Apotea AB (publ) is 27.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Apotea AB (publ) (APOTEA)?
On an EBIT basis the return on assets of Apotea AB (publ) is 59.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Apotea AB (publ) (APOTEA)?
The operating margin of Apotea AB (publ) is 5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Apotea AB (publ) (APOTEA)?
Revenue at Apotea AB (publ) is growing +10.9% versus a year earlier (3y avg +13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Apotea AB (publ) (APOTEA)?
Earnings per share at Apotea AB (publ) are growing +13.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Apotea AB (publ) (APOTEA) carry?
The net debt of Apotea AB (publ) is 328M SEK (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Apotea AB (publ) in the live analysis
One click puts Apotea AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026